Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

DCprime

Request full access

DCprime – We help shape a new era in cancer immunotherapeutics

Leiden, NetherlandsFounded 2005Biotech & Life Sciences

About DCprime

DCprime B.V. was a clinical-stage biopharmaceutical company focused on the development of cancer relapse vaccines. Founded in 2005 and headquartered in Leiden, Netherlands, the company operated in the immuno-oncology market. DCprime's business model revolved around its proprietary DCOne® technology platform, designed to create off-the-shelf, allogeneic dendritic cell-based therapies. These vaccines aimed to prevent or delay disease recurrence by stimulating a patient's immune system to recognize and attack tumor cells.

The company's core product, DCP-001, is a whole-cell-based vaccine developed for blood cancers, particularly Acute Myeloid Leukemia (AML), which showed promising results in early clinical trials. The DCOne® platform utilizes a human myeloid leukemia cell line that can be differentiated into dendritic cells, which naturally express a broad range of tumor-associated antigens. This approach allows for scalable manufacturing and provides the logistical benefits of a standardized, off-the-shelf product, in contrast to patient-specific dendritic cell vaccines. The company's strategy also included extending its vaccine applications to solid tumors and exploring combinations with other immuno-oncology treatments.

A significant milestone in the company's history was the strategic investment from Van Herk Investments in 2014, which provided crucial funding for the continued development of the DCOne® platform. Dr. Ada Kruisbeek, the founder of DCprime, initially served as both CEO and Chief Scientific Officer, later transitioning to focus solely on the scientific development as CSO. In a transformative event, DCprime was acquired by the Swedish biopharmaceutical company Immunicum AB (publ) in a deal that was completed on December 21, 2020. The acquisition was structured as a business combination to merge the complementary dendritic cell biology expertise of both companies, creating a more robust pipeline in cell-based cancer immunotherapies. Following the merger, Immunicum continued to advance the development of DCP-001 and in May 2022, rebranded to Mendus AB to reflect its maturing clinical pipeline and focus on cancer recurrence.

Source: Dealroom company data

At a glance

Status
Operational
Employees
3
Open positions
None listed
Dealroom signal
23.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Immune System, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
MERGER✓Other financing Dec 2020 $0 — Immunicum —
LATE VC✓Equity / VC Mar 2018 $17M $66M Van Herk Investments —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

DCprime website traffic

Latest recorded traffic for DCprime is 1.5K monthly website visits, down 25% over the last three months. DCprime's team grew 0% over the past year.

Latest monthly visits1.5K 3-month web change-25% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

DCprime in the Leiden ecosystem

Live from Dealroom

The DCprime office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Eureka
  • European Commission

Series A1 investor entered at this stage

  • Thuja Capital

Series B and later1 investor entered at this stage

  • Van Herk Investments

Other known investors1 additional known investor

  • Immunicum
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇳🇱 Netherlands · Leiden HQ
Book a demo for the full country breakdown

See DCprime’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.